Insulin-degrading enzyme inhibition, a novel therapy for type 2 diabetes?

  • Cell Metab. 2014 Aug 5;20(2):201-3. doi: 10.1016/j.cmet.2014.07.016.
Safia Costes  1 ,  Peter C Butler  2
Affiliations
  • 1. Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
  • 2. Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: [email protected].
PMID: 25100059 DOI: 10.1016/j.cmet.2014.07.016
Abstract

The insulin-degrading enzyme (IDE) has been identified as a type 2 diabetes and Alzheimer's disease susceptibility gene, though its physiological function remains unclear. Maianti et al. (2014) now propose that an IDE Inhibitor may be a promising therapeutic strategy for type 2 diabetes.

Products